A carregar...
Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?
Trastuzumab has significantly improved the median survival of patients with HER2-positive breast cancer. In metastatic disease, maintenance trastuzumab is usually given after tumour response has been achieved with the combination of chemotherapy and trastuzumab, with the aim of prolonging time to di...
Na minha lista:
| Publicado no: | BMJ Case Rep |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4460523/ https://ncbi.nlm.nih.gov/pubmed/26040825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2014-207750 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|